Oragenics Appoints Al Fosmoe as Senior Vice President of Operations/Product Development
Oragenics Continues to Focus on the Development of New Lantibiotics
TAMPA, Fla.-- Oragenics, Inc. (NYSE:MKT - OGEN), a leader in the development of novel, effective antibiotics and oral care probiotics, today announced that Mr. Al Fosmoe has joined Oragenics as Senior Vice President Operations/Product Development. The appointment is directly related to the progress Oragenics has made in the development of a new pipeline of novel antibiotics from its lantibiotic platform, and marks the expansion of the team dedicated to accelerating the progress of the lantibiotic pipeline.
Mr. Fosmoe brings to Oragenics more than 25 years of product development, regulatory and commercialization experience in the regulated healthcare products sector, including biologics and drugs. His background spans operational and regulatory oversight for the development of live biotherapeutic products (LBP), biotechnology-derived products, and various oral care products, as well as advancing drug candidates through US and EU clinical trials.
Mr. Fosmoe commented, “I am excited by the opportunity to bring a new class of antibiotics to the market in an environment where these compounds may serve both existing and future unmet medical needs, and could potentially help stave off infections around the world. Oragenics has an exciting pipeline and the scientific wherewithal, especially through our collaboration with Intrexon, to move these new compounds into the clinic.”
Dr. John N. Bonfiglio, President and CEO of Oragenics, stated, “The appointment of Al Fosmoe is a milestone in the progression of Oragenics from a purely research driven company to a development stage company with a pipeline of new, potentially useful antibiotics. Together with our collaborators at Intrexon, we have begun the preclinical development of these compounds which we expect will lead to an IND filing in mid-2015.”
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health in humans and pets. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation Inc., a synthetic biology company. The collaborations will allow Oragenics access to Intrexon's proprietary technologies with the idea of accelerating the development of much needed new antibiotics that will work against resistant strains of bacteria and new therapeutic probiotics designed to alleviate symptoms from oral diseases. Oragenics also develops, markets and sells proprietary OTC probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora in more than 13 countries worldwide.
Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in the filings of Intrexon and Oragenics with the U.S. Securities and Exchange Commission. Any responsibility to update forward-looking statements is expressly disclaimed.
John N. Bonfiglio, PhD, 813-286-7900 x232
Chief Executive Officer
Investor / Media Contacts
The Ruth Group
Stephanie Carrington / Aaron Estrada, 646-536-7017/7028
email@example.com / firstname.lastname@example.org
Source: Oragenics, Inc.
Released April 22, 2014